Save your place

Sign in to WhoBought

Please try again later.

Invesco's MoonLake Immunotherapeutics (MLTX) position

Yes: as of Q1 2026, Invesco holds 140K shares of MLTX worth an amount we cannot price (0.0% of the disclosed portfolio). Last quarter the position was opened. First disclosed Q1 2023.
View full portfolio →
Current value
an amount we cannot price
Shares held
140K
% of portfolio
0.0%
Quarter-end price
No quarter-end price available

Average buy price is hidden here because at least one covered purchase quarter has no usable local mean price.

MLTX price vs Invesco's position

Dates
$18.5$19$19.5$20$20.5← Earlier —3 purchases, 2 sells
Average closing price · filing quarter
Price range · filing quarter

Every quarterly change

Quarter Action Shares change Est. value change Δ Own Shares held Filing date
Q1 2026 New +140K 140K May 12, 2026
Q4 2023 Reduced −12K −4.8% 238K Feb 13, 2024
Q3 2023 Reduced −12K −4.4% 250K Nov 13, 2023
Q2 2023 Added +85K +48.1% 262K Aug 11, 2023
Q1 2023 New +177K 177K May 12, 2023
Data through Q1 2026 · filed May 12, 2026
5 grouped rows from 5 quarters

More Invesco positions

Common questions

Does Invesco own MLTX?

Yes. As of Q1 2026, Invesco disclosed 140K shares of MLTX, worth an amount we cannot price. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.

When did Invesco buy MLTX?

Invesco first disclosed a MLTX position in Q1 2023; every quarterly buy and sell since is in the table above. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.

Did Invesco sell MLTX?

The quarter-by-quarter table above shows each sale and reduction Invesco disclosed in MLTX. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.

How many shares of MLTX does Invesco own?

Invesco disclosed 140K shares of MLTX as of Q1 2026. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.

What price did Invesco pay for MLTX?

Invesco began building the MLTX position before our 13F history starts, so an exact average buy price cannot be estimated without understating it. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.

How are the estimated trade prices calculated?

13F filings disclose quarter-end holdings, not trade dates or execution prices. These estimates use each covered quarter's average market price; the add average excludes the opening position and quarters without price data. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.